IRADIMED CORPORATION APIC, Share-based Payment Arrangement, Increase for Cost Recognition
IRADIMED CORPORATION (IRMD) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $807.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-07-31
- IRADIMED CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $807.00K, a 10.55% increase year-over-year.
- IRADIMED CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $684.00K, a 17.19% decline year-over-year.
- IRADIMED CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $666.08K, a 5.73% increase year-over-year.
- IRADIMED CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $730.00K, a 19.85% increase year-over-year.
- IRADIMED CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $2.92M, a 15.65% increase from fiscal 2024.
- IRADIMED CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $2.52M, a 15.41% increase from fiscal 2023.
- IRADIMED CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $2.19M, a 56.87% increase from fiscal 2022.
- IRADIMED CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $1.39M, a 4.47% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $807.00K 10-Q · filed 2026-07-31 | $1.49M derived: sum of 2 quarters · filed 2026-07-31 | ||||
| 2026-03-31 | $684.00K 10-Q · filed 2026-07-31 | |||||
| 2025-12-31 | $2.92M 10-K · filed 2026-03-06 | |||||
| 2025-09-30 | $666.08K 10-Q · filed 2025-11-03 | $1.40M derived: sum of 2 quarters · filed 2026-07-31 | $2.22M derived: sum of 3 quarters · filed 2026-07-31 | |||
| 2025-06-30 | $730.00K 10-Q · filed 2026-07-31 | $730.62K 10-Q · filed 2025-08-01 | $1.56M derived: sum of 2 quarters · filed 2026-07-31 | |||
| 2025-03-31 | $826.00K 10-Q · filed 2026-07-31 | $826.06K 10-Q · filed 2025-05-05 | ||||
| 2024-12-31 | $2.52M 10-K · filed 2026-03-06 | $2.52M 10-K · filed 2025-03-06 | ||||
| 2024-09-30 | $629.97K 10-Q · filed 2025-11-03 | $1.24M derived: sum of 2 quarters · filed 2025-11-03 | $1.87M derived: sum of 3 quarters · filed 2025-11-03 | |||
| 2024-06-30 | $609.10K 10-Q · filed 2025-11-03 | $1.24M derived: sum of 2 quarters · filed 2025-11-03 | ||||
| 2024-03-31 | $628.64K 10-Q · filed 2025-11-03 | |||||
| 2023-12-31 | $2.19M 10-K/A · filed 2025-09-03 | |||||
| 2023-09-30 | $533.75K 10-Q · filed 2024-10-31 | $1.10M derived: sum of 2 quarters · filed 2024-10-31 | $1.64M derived: sum of 3 quarters · filed 2024-10-31 | |||
| 2023-06-30 | $568.45K 10-Q · filed 2024-10-31 | $1.10M derived: sum of 2 quarters · filed 2024-10-31 | ||||
| 2023-03-31 | $533.64K 10-Q · filed 2024-10-31 | |||||
| 2022-12-31 | $1.39M 10-K · filed 2024-03-01 | |||||
| 2022-09-30 | $393.19K 10-Q · filed 2023-11-03 | $514.19K derived: sum of 2 quarters · filed 2023-11-03 | $967.55K derived: sum of 3 quarters · filed 2023-11-03 | |||
| 2022-06-30 | $121.00K 10-Q · filed 2023-11-03 | $574.36K derived: sum of 2 quarters · filed 2023-11-03 | ||||
| 2022-03-31 | $453.36K 10-Q · filed 2023-11-03 | |||||
| 2021-12-31 | $1.46M 10-K · filed 2023-03-02 | |||||
| 2021-09-30 | $361.84K 10-Q · filed 2022-11-03 | $719.85K derived: sum of 2 quarters · filed 2022-11-03 | $1.07M derived: sum of 3 quarters · filed 2022-11-03 | |||
| 2021-06-30 | $358.01K 10-Q · filed 2022-11-03 | $705.75K derived: sum of 2 quarters · filed 2022-11-03 | ||||
| 2021-03-31 | $347.74K 10-Q · filed 2022-11-03 | |||||
| 2020-12-31 | $3.96M 10-K · filed 2022-03-04 | |||||
| 2020-09-30 | $416.52K 10-Q · filed 2021-11-05 | $3.08M derived: sum of 2 quarters · filed 2021-11-05 | $3.64M derived: sum of 3 quarters · filed 2021-11-05 | |||
| 2020-06-30 | $2.66M 10-Q · filed 2021-11-05 | $3.23M derived: sum of 2 quarters · filed 2021-11-05 | ||||
| 2020-03-31 | $568.96K 10-Q · filed 2021-11-05 | |||||
| 2019-12-31 | $1.85M 10-K · filed 2022-03-04 | |||||
| 2019-09-30 | $455.64K 10-Q · filed 2020-11-06 | $924.08K derived: sum of 2 quarters · filed 2020-11-06 | $1.31M derived: sum of 3 quarters · filed 2020-11-06 | |||
| 2019-06-30 | $468.44K 10-Q · filed 2020-11-06 | $850.79K derived: sum of 2 quarters · filed 2020-11-06 | ||||
| 2019-03-31 | $382.35K 10-Q · filed 2020-11-06 | |||||
| 2018-12-31 | $1.76M 10-K · filed 2021-03-05 | |||||
| 2018-03-31 | $416.33K 10-Q · filed 2019-05-08 | |||||
| 2017-12-31 | $2.45M 10-K · filed 2020-03-06 | |||||
| 2016-12-31 | $1.84M 10-K · filed 2019-03-07 | |||||
| 2015-12-31 | $1.22M 10-K · filed 2018-03-08 | |||||
| 2014-12-31 | $220.18K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | $724.06K 10-K · filed 2017-03-10 | ||||
| 2014-09-30 | $503.88K 10-Q · filed 2014-11-13 | |||||
| 2013-12-31 | $271.92K 10-K · filed 2015-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |